QuiVad

Home / Funds / Guevoura Fund

Guevoura Fund

The short positions this fund discloses today, across every market.

Follow

Open short positions, the heaviest first.
IssuerMarket% of capitalSince
Precise Biometrics ABSweden0.75%August 10, 2026

History of disclosures

310 disclosures on record for this fund.
DateIssuerMarket% of capitalEnd of publication
August 10, 2026Precise Biometrics ABSweden0.75%still open
August 6, 2026Precise Biometrics ABSweden0.65%still open
June 29, 2026Intrum ABSweden1.09%still open
June 26, 2026Aktiebolaget ElectroluxSweden0.61%still open
June 25, 2026Aktiebolaget ElectroluxSweden1.67%still open
June 24, 2026Intrum ABSweden0.95%still open
June 23, 2026Aktiebolaget ElectroluxSweden1.56%still open
June 23, 2026Intrum ABSweden0.88%still open
June 22, 2026Aktiebolaget ElectroluxSweden1.45%still open
June 22, 2026Intrum ABSweden0.71%still open
June 22, 2026Dicot Pharma ABSweden0.66%still open
June 18, 2026Intrum ABSweden0.67%still open
June 17, 2026Aktiebolaget ElectroluxSweden1.31%still open
June 17, 2026Dicot Pharma ABSweden1.10%still open
June 17, 2026Intrum ABSweden0.56%still open
June 16, 2026Dicot Pharma ABSweden1.02%still open
June 12, 2026Precise Biometrics ABSweden1.01%still open
June 12, 2026Dicot Pharma ABSweden0.92%still open
June 11, 2026Aktiebolaget ElectroluxSweden1.23%still open
June 11, 2026Dicot Pharma ABSweden0.87%still open
June 10, 2026Precise Biometrics ABSweden0.96%still open
June 10, 2026Aktiebolaget ElectroluxSweden0.90%still open
June 9, 2026Aktiebolaget ElectroluxSweden0.75%still open
June 9, 2026Dicot Pharma ABSweden0.66%still open
June 8, 2026Precise Biometrics ABSweden0.81%still open
June 4, 2026Precise Biometrics ABSweden0.79%still open
June 4, 2026Dicot Pharma ABSweden0.51%still open
March 24, 2026Oncopeptides ABSweden1.37%still open
March 20, 2026Oncopeptides ABSweden1.50%still open
March 19, 2026Oncopeptides ABSweden1.49%still open
March 18, 2026Oncopeptides ABSweden1.87%still open
March 17, 2026Oncopeptides ABSweden1.33%still open
March 16, 2026Oncopeptides ABSweden0.81%still open
March 16, 2026Nobia ABSweden0.50%still open
March 12, 2026Oncopeptides ABSweden0.54%still open
March 10, 2026Cell Impact AB (publ)Sweden1.23%still open
March 9, 2026Cell Impact AB (publ)Sweden1.10%still open
March 6, 2026Cell Impact AB (publ)Sweden0.99%still open
March 5, 2026Cell Impact AB (publ)Sweden1.43%still open
March 4, 2026Cell Impact AB (publ)Sweden1.30%still open
March 4, 2026Kjell Group AB (publ)Sweden0.55%still open
March 3, 2026Cell Impact AB (publ)Sweden1.28%still open
February 27, 2026Cell Impact AB (publ)Sweden1.03%still open
January 28, 2026Midsummer ABSweden0.72%still open
January 26, 2026Midsummer ABSweden0.67%still open
December 22, 2025Active Biotech AB (publ)Sweden1.25%still open
December 16, 2025Active Biotech AB (publ)Sweden2.68%still open
December 15, 2025Active Biotech AB (publ)Sweden2.59%still open
December 11, 2025Active Biotech AB (publ)Sweden2.42%still open
December 10, 2025Active Biotech AB (publ)Sweden2.40%still open

Download as CSV

Cite this page

The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.

QuiVad, Guevoura Fund, data as at August 10, 2026, https://www.quivad.com/detenteur/guevoura-fund